David Ramsey
Ophthalmology · Burlington, MANPI 1881861789
Payments from drug & device makers
Across 52 payments — averaging $230.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$8K
- Beaver-visitec International, Inc.$2K
- Genentech USA, Inc.$395
- Regeneron Healthcare Solutions, Inc.$384
- Astellas Pharma US Inc$217
- Alimera Sciences, Inc.$162
- plus $699 from 10 others
What the payments were for
- Consulting fees$10,26086%
- Travel & lodging$160%
- Food & beverage$1,62814%
- Education$150%
- Entertainment$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 5 | $8,460 |
| Beaver-visitec International, Inc. | 2 | $1,650 |
| Genentech USA, Inc. | 13 | $395 |
| Regeneron Healthcare Solutions, Inc. | 9 | $384 |
| Astellas Pharma US Inc | 5 | $217 |
| Alimera Sciences, Inc. | 5 | $162 |
| Cardinal Health 110 LLC | 1 | $150 |
| Alcon | 2 | $150 |
| Novartis | 2 | $121 |
| Apellis Pharmaceuticals, Inc. | 1 | $88 |
| Optos, Inc. | 1 | $49 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| AbbVie | 1 | $33 |
| Coherus Oncology, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,968 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 100 | $3,995 |
| Ketorolac Tromethamine | 90 | $1,211 |
| Difluprednate | 20 | $1,085 |
| Dorzolamide Hcl | 49 | $805 |
| Latanoprost | 60 | $390 |
| Ofloxacin | 25 | $347 |
| Timolol Maleate | 35 | $319 |
| ErythromycinErythromycin Base | 30 | $315 |
| Brimonidine Tartrate | 38 | $273 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $233 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $233 |
| Cyclopentolate Hcl | 11 | $204 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Burlington
- Kendra Klein-MasciaBurlington$73K
- Gail TorkildsenAndover$5.1M
- David LallySpringfield$4.5M
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Rachel HuckfeldtStoneham$1.7M
- Mark AbelsonAndover$1.3M
- Peter ChangWaltham$1M
- Stephen AnesiWaltham$922K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.